Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review)

Coleman, Emily; Olamiju, Brianna; Leventhal, Jonathan S.

doi:10.3892/or.2020.7911

Cited by 10 publications

(2 citation statements)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While most skin reactions are non-life threatening, severe cutaneous adverse reactions may also occur. They include SJS, toxic epidermal necrolysis (TEN), DRESS and acute generalized exanthematous pustulosis (AGEP) [ 20 ]. These drugs are toxic by nature.…”

Section: Discussionmentioning

confidence: 99%

Successful Desensitization to Sorafenib and Imatinib—A Report of Two Cases and a Literature Review

Kusic,

Tomic Spiric,

Arandjelovic

et al. 2024

Healthcare

View full text Add to dashboard Cite

Background: Drug desensitization allows for safe administration of a drug to a patient with a previous hypersensitivity reaction. Successful desensitization protocols have been described for different medications, including protocols for oncology patients. Few cases of desensitization to sorafenib and imatinib have been described in the literature so far. Objective: The objective of this paper is to describe the process of the sorafenib and imatinib drug hypersensitivity diagnosis and desensitization process in two patients. Methods: Two oncology patients who experienced non-immediate hypersensitivity reactions to sorafenib and imatinib underwent desensitization to these drugs. We designed a protocol for the first patient and used a modified protocol from the literature for the second patient. Results: By using a slow desensitization technique and gradual tapering of corticosteroids and antihistamines, both patients reached the target dose of the incriminated drug. Conclusions: Desensitization to sorafenib and imatinib can be an effective therapeutic option in patients with hypersensitivity to those medications, without alternative treatment options.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful Desensitization to Sorafenib and Imatinib—A Report of Two Cases and a Literature Review

Kusic,

Tomic Spiric,

Arandjelovic

et al. 2024

Healthcare

View full text Add to dashboard Cite

show abstract

“…These agents include inhibitor of BCR-ABL, epidermal growth factor receptor (EGFR), plateletderived growth factor (PDGFR), c-Kit, vascular endothelial growth factor (VEGF), and human epidermal growth factor receptor 2 (HER2). In parallel with the evolving applications of these receptors, cutaneous toxicities associated with these agents have become more well-known [116]. In this section, we provide an overview of DTH reactions related to tyrosine kinase inhibitors.…”

Section: Signal Transduction Inhibitorsmentioning

confidence: 99%

Evaluation of Delayed-Type Hypersensitivity to Antineoplastic Drugs—An Overview

Roger

Montero

Pérez-Leal

et al. 2023

Cancers

View full text Add to dashboard Cite

Nowadays, clinical practice encounters the problem of delayed-type hypersensitivity (DTH) induced by several drugs. Antineoplastic treatments are among the drugs which show an elevated proportion of DHT reactions, leading to the worsening of patients’ quality of life. The range of symptoms in DHT reactions can vary from mild, such as self-limiting maculopapular eruptions, to severe, such as Stevens–Johnson Syndrome. The development of these reactions supposes a negative impact, not only by limiting patients’ quality of life, but also leading to economic loss due to market withdrawal of the affected drugs and high hospitalization costs. However, despite this problem, there are no available standard in vitro or in vivo methods that allow for the evaluation of the sensitizing potential of drugs in the preclinical phase. Therefore, the aim of this review is to summarize the skin reactions caused by the different antineoplastic families, followed by a comprehensive evaluation of the in vitro and in vivo methods used to detect DTHs and that could be suitable to test antineoplastic hypersensitivity reactions.

show abstract

Psoriasis in the Era of Targeted Cancer Therapeutics: A Systematic Review on De Novo and Pre-existing Psoriasis in Oncologic Patients Treated with Emerging Anti-neoplastic Agents

Madan,

Ortiz-López,

Sakunchotpanit

et al. 2024

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

New advancements in medicine have paved the way for targeted therapies and immune checkpoint inhibitors (ICIs), which have become mainstays of cancer therapy. Targeted therapies work by pinpointing specific molecules in cancer pathways and inhibiting their function, while ICIs target irregularities in the immune system and DNA repair, participating in the induction of cell death. Although these agents have demonstrated great efficacy in treating a diverse set of cancers, they can frequently provoke serious dermatologic adverse effects. The side effects caused by an ICI are classified as immune-related adverse events since ICIs are immunomodulating, while the cutaneous side effects of targeted therapies are known as dermatologic adverse effects. Multiple studies have reported psoriasis and psoriasiform eruptions among the side effects observed in neoplastic patients receiving targeted therapies or ICIs. Psoriasis is an immune-mediated disease characterized by overactive T-cells and keratinocytes. To conduct this review, we retrieved 1363 studies from the PubMed database published between 2008 and 2023 using the terms “psoriasis” AND “cancer treatment.” Many of these studies aimed to understand how patients with cancer receiving treatment may develop or even achieve psoriasis remission. Given that cancer and psoriasis involve a delicate balance between immune activation and suppression, ICIs and targeted therapies might produce varying effects. The aim of this review was to explore the relationship between psoriasis and cancer therapeutics while also highlighting the need to prioritize proper management of cutaneous side effects in neoplastic patients.

show abstract

Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review)

Cited by 10 publications

References 117 publications

Successful Desensitization to Sorafenib and Imatinib—A Report of Two Cases and a Literature Review

Successful Desensitization to Sorafenib and Imatinib—A Report of Two Cases and a Literature Review

Evaluation of Delayed-Type Hypersensitivity to Antineoplastic Drugs—An Overview

Psoriasis in the Era of Targeted Cancer Therapeutics: A Systematic Review on De Novo and Pre-existing Psoriasis in Oncologic Patients Treated with Emerging Anti-neoplastic Agents

Contact Info

Product

Resources

About